focus -WSS

focus

author：comprehensive 2025-10-02 19:27:18 Page View：28581

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Who gets to use the title 'doctor'?
Next article： Anesthesiologist group: stop taking Ozempic before surgery

focus

ChatGPT in medicine: STAT answers readers' burning questions

MikeReddyforSTATArtificialintelligenceisoftendescribedasablackbox:anunknowable,mysteriousforcethatop

Does aspartame cause cancer? What new WHO guidance says

MattRourke/APWASHINGTON—Aspartame,thepopularartificialsweetenerindietsodasandchewinggums,maypossibly

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

Raw milk easy to obtain despite bird flu warning, FDA interstate ban

ReporterNicholasFlorkoholdsthejugof"petmilk"fromMarylandthathepickedupinWashington,D.C.NicholasFlork

focus

leisure time

focus

Raw milk easy to obtain despite bird flu warning, FDA interstate ban